A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Public ClinicalTrials.gov record NCT00870870. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.
Study identification
- NCT ID
- NCT00870870
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- Gemcitabine Drug
- Cisplatin Drug
- IMC-A12 (cixutumumab) Biological
- Cetuximab Biological
- Carboplatin Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Mar 31, 2012
- Completion
- Apr 30, 2012
- Last update posted
- May 31, 2018
2009 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Anniston | Alabama | 36207 | — |
| ImClone Investigational Site | La Jolla | California | 92093 | — |
| ImClone Investigational Site | Orange | California | 92868 | — |
| ImClone Investigational Site | Orlando | Florida | 32806 | — |
| ImClone Investigational Site | Atlanta | Georgia | 30341 | — |
| ImClone Investigational Site | Chicago | Illinois | 60612 | — |
| ImClone Investigational Site | Chicago | Illinois | 60637 | — |
| ImClone Investigational Site | Albuquerque | New Mexico | 87131 | — |
| ImClone Investigational Site | New York | New York | 10011 | — |
| ImClone Investigational Site | New York | New York | 10021 | — |
| ImClone Investigational Site | New York | New York | 10032 | — |
| ImClone Investigational Site | Cincinnati | Ohio | 45247 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00870870, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2018 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00870870 live on ClinicalTrials.gov.